New Super-Vaccine trial aims to protect babies from more pneumonia strains
NCT ID NCT06800261
Summary
This study is testing a new 24-valent pneumococcal conjugate vaccine (PCV24) in healthy children aged 2 to 23 months. The main goal is to check if the vaccine is safe and if it triggers a good immune response to protect against pneumococcal diseases like pneumonia and meningitis. Researchers will compare it to an existing vaccine (Prevenar13) in about 180 children.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMOCOCCAL INFECTIOUS DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shandong Provincial Center for Disease Control and Prevention
NOT_YET_RECRUITINGJinan, Shandong, 250014, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shanxian Center for Disease Control and Prevention
RECRUITINGShancheng, Shandong, 250014, China
Contact
Conditions
Explore the condition pages connected to this study.